Prostate cancer highlights from the American Urological Association 2025 meeting include quality-of-life results from the phase 3 PSMAfore study, findings on androgen deprivation therapy (ADT) with or without darolutamide, and data on the prostate-specific membrane antigen (PSMA)–targeted radionuclide J591, as reported by Dr Brian Rini of Vanderbilt University in Nashville, Tennessee.
Dr Rini begins with health-related quality-of-life results reported in the PSMAfore study examining 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Patients in the lutetium arm showed a delay to first symptomatic skeletal event with or without concomitant bisphenol A. There was also a shorter median time to improvement in pain and a favorable safety profile vs changes seen in patients receiving androgen receptor pathway inhibition.
Next, Dr Rini reviews an analysis of the ARANOTE study, which looked at ultra-low prostate-specific antigen (PSA) response to ADT with or without darolutamide. Five times more ultra-low PSA responses were seen with darolutamide plus ADT vs ADT alone, and rates of PSA < 0.02 ng/mL were higher with darolutamide vs placebo regardless of baseline PSA.
Finally, Dr Rini reviews data on the radionuclide J591, which is a PSMA-targeted actinium-225 therapy. He reports that when J591 is used in combination with other agents, there appears to be greater progression-free and overall survival vs single-agent therapy.
